The Cytokine Storm Company

Lenzilumab, COVID-19, and Cytokine Storm

Q&A Series

About Us

We are a clinical stage biopharmaceutical company, developing our immunology and immuno-oncology portfolio of monoclonal antibodies. We are focusing our efforts on the development of our lead product candidate, lenzilumab, our proprietary Humaneered® (“Humaneered”) anti-human granulocyte-macrophage colony-stimulating factor (“GM-CSF”) monoclonal antibody.

Are you or a loved one seeking a treatment for COVID-19?

Visit StopStorm.com

To learn about Humanigen's Phase 3 Clinical Trial

View Map

of lenzilumab clinical trial sites

Statement from Humanigen
Updated December 15, 2020

​

Emergency Use Authorization of Pfizer and BioNTech’s COVID-19 vaccine represents a significant step forward in COVID-19 prevention and all of us at Humanigen applaud the collective efforts that went in to making this a reality. 

​

While we celebrate this important milestone, we also recognize that with over 100 thousand hospitalized  in the U.S. and more than 73 million cases of COVID-19 worldwide, the need for COVID-19 therapeutics remains critical and we must continue to advance the development and manufacturing of therapeutics to turn the tide in this pandemic. 

​

Humanigen is intensely focused on developing our investigational Phase 3 treatment candidate, lenzilumab™, to prevent and treat an immune hyper-response called cytokine storm, which has been responsible for some of the most severe and deadly symptoms of COVID-19. 

To learn more about our lead treatment candidate, lenzilumab or to find a clinical trial near you, visit: stopstorm.com.